We show that loss of KEAP1 reduces sensitivity of RET fusion-positive PTC cells to the receptor tyrosine kinase inhibitor selpercatinib, a key therapeutic agent for RET-driven thyroid cancers. Here, KEAP1 is linked to thyroid gland carcinoma.